Vivesto AB (Vivesto AB) Inventories, Other : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Vivesto AB's other inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.

Vivesto AB's annual other inventories declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Vivesto AB Inventories, Other Historical Data

The historical data trend for Vivesto AB's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Inventories, Other Chart

Vivesto AB Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Inventories, Other

Get a 7-Day Free Trial

Vivesto AB Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventories, Other	Get a 7-Day Free Trial															-	-	-	-	-

Vivesto AB Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Vivesto AB (Vivesto AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Inventories, Other

Comparable Companies

Traded in Other Exchanges

VIVE:Sweden OMAX:Germany

Address

Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73

Website

https://www.vivesto.com

Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.